Trump Asks Drugmakers to Voluntarily Lower US Prices, but Will They Comply?
Drug companies were nervously awaiting President Trump's announcement on pharmaceutical tariffs, but instead, he signed a "better than feared" executive order on Monday. According to the New York Times, Trump wants US drug companies to voluntarily reduce US prices.
Despite having no real legal authority to enact this, the executive order did say that if drugmakers do not lower US prices, the Trump administration would consider imposing regulations or importing drugs from other countries.
On Sunday, Trump stated in a Truth Social post that he would employ a "most favored nation's policy," in which the US will pay the same price as the nation that pays the lowest price. This caused pharmaceutical stocks to go up on Monday morning.
"I'm not knocking the drug companies," Trump said, per the NYT. "I'm really more knocking the countries than the drug companies."
With this in mind, the executive order also asks federal agencies to look into why European countries have lower prices. Trump said he would use trade policy to get these countries to pay more. However, since drugmakers already have contracts with these governments, it's not clear how this would be enforced.
According to pharmaceutical companies, higher drug prices in the US allow people to get their prescriptions faster and with fewer insurance restrictions.
"Most favored nation is a deeply flawed proposal that would devastate our nation's small- and mid-size biotech companies, the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America's biotechnology leadership," said John F. Crowley, president and CEO of the Biotechnology Innovation Organization, in a statement.
On the other hand, the NYT reports that Stephen J. Ubl, chief executive of PhRMA, a US trade group representing pharmaceutical companies, stated, "US patients should not foot the bill for global innovation," and that foreign governments should have "to pay their fair share for medicines."
Only time will tell how and if this executive order will be enacted and whether US drug companies will voluntarily lower their prices for American patients. In the meantime, we will be waiting for Trump's pharmaceutical tariff announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
AMD Acquires Another Company To Expand AI Arsenal
Advanced Micro Devices, Inc (NASDAQ:AMD) on Wednesday announced the acquisition of Brium, a team of compiler and AI software experts with deep expertise in machine learning, AI inference, and performance optimization. The financial terms of the transaction remain undisclosed. Brium brings advanced software capabilities that strengthen AMD's ability to deliver highly optimized AI solutions across the entire stack. Their work in compiler technology, model execution frameworks, and end-to-end AI inference optimization will play a key role in enhancing the efficiency and flexibility of AMD's AI acquisition marks the latest in a series of targeted investments, following AMD's acquisitions of Silo AI, and Mipsology, that boosts its ability to support the open-source software ecosystem and deliver optimized performance on its hardware. Last week, AMD announced the acquisition of Enosemi, a move to accelerate co-packaged optics innovation for AI systems. The financial terms of the deal remain undisclosed. AMD held $6.06 billion in cash and equivalents as of March 29, 2025. AMD stock plunged 29% in the last 12 months as it grappled with intensifying rivalry from Nvidia Corp (NASDAQ:NVDA), a cooling tech rally, and the Trump administration's tariff policies. AMD reported first-quarter revenue of $7.44 billion, up 36%, beating analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share. AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion. Price Action: AMD stock is trading higher by 0.42% to $119.08 premarket at last check Thursday. Read Next:Photo by jamesonwu1972 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ADVANCED MICRO DEVICES (AMD): Free Stock Analysis Report This article AMD Acquires Another Company To Expand AI Arsenal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
20 minutes ago
- Forbes
What's Behind Newmont Mining's 44% Surge?
CANADA - 2025/03/23: In this photo illustration, the Newmont Mining Corporation logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Newmont (NYSE:NEM)'s stock has experienced quite a bit of volatility this year. It began the year on a weak note, primarily impacted by declining gold prices and concerns regarding costs and production delays. However, things started to improve as gold prices surged—thanks to global uncertainty and increased purchases by central banks. Thus far in 2025, NEM has made a solid recovery, regaining a significant portion of its previous losses. Although it isn't breaking records, it's now in a more favorable position than it was at the beginning of the year, with a year-to-date gain of 44%. The movement in Newmont's stock price aligns with that of its peers, which include Wheaton Precious Metals (NYSE:WPM) that has risen 58% and Barrick Gold (NYSE: B) that has increased by 20% in the same timeframe. Newmont Corporation's stock has seen a recent increase due to a variety of factors. Gold prices have surged nearly 30% year-to-date, recently exceeding $3,500 per ounce. This surge is driven by global economic uncertainties, such as a U.S. trade conflict with China and political tensions surrounding Federal Reserve policy. As a major gold producer, Newmont directly benefits from higher gold prices, which enhance its revenues and profitability. Buy or Sell NEM. In 2023, Newmont finalized the acquisition of Newcrest Mining, developing an industry-leading portfolio with a long-term gold and copper production profile. The integration of Newcrest is anticipated to provide significant value to shareholders, with estimated pre-tax benefits of $500 million annually by the end of 2025. Furthermore, Newmont has been selling non-core assets, generating substantial proceeds to bolster its primary operations and financial standing. Additionally, for investors seeking potential returns with reduced volatility, the High Quality portfolio has comfortably outperformed the S&P 500, providing over 91% returns since its inception. Part of the increase observed in the last five months can be attributed to strong performance in the first quarter of 2025, propelled by soaring gold prices and strategic asset management. Revenue reached $5.01 billion, exceeding expectations by nearly $440 million. Adjusted EPS was recorded at $1.25, surpassing the consensus estimate of $0.71. Although Newmont has experienced significant revenue growth since 2021, its price-to-sales (PS) multiple has declined, dropping from 3.6x in 2021 to 2.2x in 2024. While the current PS is now 3.2x, there is potential for upside when comparing the current PS to historic levels: 3.6x at the close of 2020 and 2021. In Q1 2025, Newmont reported impressive financial results, driven by record-setting gold prices and effective portfolio optimization. The company announced adjusted EPS of $1.25, significantly exceeding analyst expectations, and revenue of $5.01 billion, which was supported by an average realized gold price of $2,944 per ounce. While gold production declined by 8% year-over-year to 1.5 million ounces, primarily due to divestitures of non-core assets, the company still achieved strong profitability, reporting $2.6 billion in adjusted EBITDA and $1.2 billion in free cash flow. Newmont successfully executed key divestitures—such as the Éléonore and Akyem mines—raising over $2.5 billion in proceeds and reducing its long-term debt by $1 billion. Additionally, it returned $1 billion to shareholders through dividends and buybacks. This strong performance reaffirmed confidence in Newmont's guidance for 2025 and supported the stock's recent upward trend. We currently estimate Newmont's valuation to be approximately $60 per share, about 8% above the current market price. Focusing on valuation in addition to growth is just one of the several strategies we utilize when constructing Trefis High Quality (HQ) Portfolio which, comprising a selection of 30 stocks, has shown a history of consistently outperforming the S&P 500 over the previous 4-year period. Why is that? As a group, HQ Portfolio stocks delivered superior returns with lower risk compared to the benchmark index; providing a smoother ride, as indicated in the HQ Portfolio performance metrics.
Forbes
20 minutes ago
- Forbes
Mixus AI Agent Tool Includes Human Intervention
is a collaborative artificial intelligence platform that incorporate human participation to ... More help ensure accuracy of results. In the world of artificial intelligence, when the technology spits out inaccurate information, instead of calling it what it is, a screw up, the industry invented a softer euphemism—hallucination. Those hallucinations have the potential of causing physical or financial harm, or at the least, a major embarrassment. But a months-old startup called has added a very analog backstop to catching errors before they do any harm—the human brain. Indeed, its name is a portmanteau of mix and us, meaning blending artificial with human intelligence to help ensure accuracy. The simple explanation is when a user makes an AI query, in addition to a AI-generated response also recommends people who have expertise, experience or knowledge on the specific topic. The user can then add those recommended people into their chat and converse with them and AI together. Building on that original model, has now added an even more powerful tool it calls 'colleague in the loop' AI agents, which can conduct a vast array of tasks such as generating social media posts, emails or lists, to name a few. The twist is, the content goes nowhere until trusted human beings in a user's network act as editors and fact-checkers. co-creators Shai Magzimof (left) and Elliot Katz. 'By bringing colleagues into the loop, you get the full power of AI agents, the efficiency and the time savings, etc, without the any of that downside risk of AI mistakes going undetected,' explained Elliot Katz, who co-founded with Shai Magzimof. Creating AI agents on mixus does not require any sort of coding or programming knowledge, just the ability to read and write. 'The beauty of this is someone who's never used AI, someone who doesn't even know what an AI agent is, you can create, can build and use agents on mixus,' declared Katz, in an interview. In the video below, Katz demonstrates how a colleague in the loop AI agent is created in mixus. There's no shortage of examples of the volume of AI hallucinations causing companies and individuals to swoon from their effects. A report released in April by OpenAI, which operates the popular ChatGPT platform, revealed its o3 model hallucinated over 50% of the time, meaning every other answer was incorrect. And OpenAI's o4-mini model performed even worse: nearly four out of five responses were wrong, meaning it fabricated answers nearly 80% of the time. A very recent example occurred just last month when a summer reading list written by a syndicated freelance writer using AI appeared in such major market newspapers as the Chicago Sun-Times and Philadelphia Inquirer. As reported in the Sun-Times, the writer admitted he never double-checked the results of his AI search which was incredibly unfortunate because several of the book titles in the list never actually existed, making the AI-generated summaries equally false. Katz contends it's an example of a situation that could have been prevented by use of the colleague in the loop system. 'They could be using mixus, and they could have rules that are brought out through mixus, that say, before you publish anything, you have to have your editor or a colleague or multiple colleagues press that verify button, meaning they've actually reviewed they know that what the AI put out is real and not total slop, etc,' Katz said. Investors are backing the playbook. The company just closed its $2.6 million pre-seed funding round which included participation by Liquid 2, former NFL star quarterback Joe Montana's venture capital firm. Access to is by subscription. The company offers a free, 14-day trial to individuals using a business or personal email address. After that period, anyone who wants to continue as a user will need to contact mixus for 'custom pricing,' according to Katz. Since launching late last year, has changed its business model from B to C, targeting consumers, to now targeting businesses, for which, errors can be more consequential according to Katz. That doesn't mean individuals who are self-employed or are freelancers can't sign up. They just can't do so alone. It's all based on maintaining the collaborative nature of the site. 'You have to sign up with four other people, because that's key. We want colleagues in the loop,' said Katz. 'We are working with businesses that want to deploy AI in an AI agents in a way that they don't have to deal with these undetected AI mistakes.' You can listen or watch the entire interview with Elliot Katz and an extended demonstration of the colleague in the loop AI agent creation tool in the author's podcast Tales From the Beat.
